New combinations for mantle cell lymphoma: concerted action needed.

摘要

Mantle ceil lymphoma is one of the most difficult to treat subtypes of non-Hodgkin lymphoma; most patients ultimately die from the disease. Although, progress has been made-eg, optimised first-line therapies resulting in long-term remissions-the response of patients to subsequent traditional therapies is often disappointing. New hope came with the introduction of novel agents into the treatment of mantle cell lymphoma: therapeutic advances have been achieved in trials of bortezomib, ienalidomide, and temsirolimus, which proved that these drugs all have single-agent activity in advanced disease.However, because of the heterogeneity of these trials, their results are hard to compare and, to date, only temsirolimus has proved to be effective in comparison to standard treatments in a phase 3 trial.